CLAIMS

1. A therapeutic agent for nerve damage comprising, as an active ingredient, a low-molecular-weight saccharide composed of at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof.

2. The therapeutic agent according to claim 1, wherein the low-molecular-weight saccharide composed at least glucuronic acid and/or N-acetylglucosamine is a low-molecular-weight hyaluronic acid.

3. The therapeutic agent according to claim 2, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid disaccharide to hyaluronic acid 2,500-saccharide.

4. The therapeutic agent according to claim 3, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid disaccharide to hyaluronic acid 50-saccharide.

5. The therapeutic agent according to claim 4, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid tetrasaccharide.

6. The therapeutic agent according to any one of claims 1 to 5, wherein nerve damage is caused by spinal cord injury or nerve trauma.

7. A method of treating nerve damage, comprising administering an effective amount of a low-molecular-weight saccharide composed of at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof to an animal suffering from nerve damage.

8. Use of a low-molecular-weight saccharide composed of at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof in manufacturing a therapeutic agent for nerve damage.